AMR Action Fund | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/AMR Action Fund/Activity

AMR Action Fund Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

Essay

Published an op-ed on how antimicrobial resistance is disrupting cancer care across Europe.

How AMR is disrupting cancer care across Europe

AMR Action Fund

amractionfund.comAUG 5, 2026

AUG 5, 2026

3 investments

· FEB 2026 – JUL 2026

Show all

Investment

Participated in Trellis Bioscience's $9M raise to advance a Phase 2 trial of a monoclonal antibody for prosthetic joint infections.

Trellis Bioscience

Trellis Bioscience AMR Action Fund

amractionfund.comJUL 16, 2026

JUL 16, 2026

Investment

Led Telum Therapeutics' €18 million Series A financing round to advance treatments for hospital-acquired infections.

Telum Therapeutics

Telum Therapeutics AMR Action Fund

amractionfund.comJUL 1, 2026

JUL 1, 2026

Investment

Invested £6M to extend Centauri Therapeutics' Series A to £30M, supporting its lead clinical candidate.

Centauri Therapeutics

Centauri Therapeutics AMR Action Fund

businesswire.comFEB 24, 2026

FEB 24, 2026

Milestone

Portfolio company Venatorx Pharmaceuticals out-licensed its Phase 3-ready oral antibiotic ceftibuten-ledaborbactam etzadroxil to Basilea Pharmaceutica for up to $325M in milestones.

Venatorx Pharmaceuticals

Venatorx Pharmaceuticals AMR Action Fund

globenewswire.comAUG 14, 2025

AUG 14, 2025

Exit

Portfolio company Utility Therapeutics was acquired by Alembic Pharmaceuticals following FDA approval of its lead antibiotic PIVYA.

Utility Therapeutics

Utility Therapeutics AMR Action Fund

biospace.comJUL 3, 2025

JUL 3, 2025

Investment

Co-led Elion Therapeutics' $81 million Series B funding round alongside Deerfield Management.

Elion Therapeutics

Elion Therapeutics AMR Action Fund

prnewswire.comJUN 17, 2024

amractionfund.com

JUN 17, 2024

Milestone

Portfolio company Utility Therapeutics received FDA approval for pivmecillinam (PIVYA), the first new antibiotic approved for uncomplicated UTI in roughly 20 years.

Utility Therapeutics

Utility Therapeutics AMR Action Fund

amractionfund.comAPR 2024

APR 2024

News

Opened its first European office in Basel, Switzerland to expand sourcing and support for European antibiotic R&D.

AMR Action Fund opens European office in Basel

AMR Action Fund

amractionfund.comFEB 7, 2022

FEB 7, 2022